ABBV,AbbVie, Neurocrine drug successful in endometriosis trialUPDATE 1-AbbVie, Neurocrine drug successful in endometriosis trialAbbVie, Neurocrine drug successful in endometriosis trialAbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.    AbbVie, Neurocrine drug successful in endometriosis trialAbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   Jan 8 An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc  successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie, Neurocrine drug successful in endometriosis trialAbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.     UPDATE 1-AbbVie, Neurocrine drug successful in endometriosis trialAbbVie, Neurocrine drug successful in endometriosis trialAbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.    AbbVie, Neurocrine drug successful in endometriosis trialAbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   Jan 8 An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc  successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie, Neurocrine drug successful in endometriosis trialAbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.    Jan 8 An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc  successfully reduced symptoms of endometriosis in premenopausal women in the first of two late-stage studies.UPDATE 1-AbbVie, Neurocrine drug successful in endometriosis trialAbbVie, Neurocrine drug successful in endometriosis trialAbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.    AbbVie, Neurocrine drug successful in endometriosis trialAbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   Jan 8 An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc  successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie, Neurocrine drug successful in endometriosis trialAbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.   AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.AbbVie forecasts 2015 earnings largely above analysts' estimateUPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.  UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.UPDATE 1-AbbVie forecasts 2015 earnings largely above analysts' estimate Jan 8 AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira.     
GOOGL,Google Capital invests in Indian property website CommonfloorGoogle Capital invests in Indian property website CommonfloorGoogle to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.  Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry. NEW DELHI Indian property search website Commonfloor.com has received funding from Google Capital, an equity fund backed by Google Inc, the online portal said in a statement on Thursday.Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.   Google Capital invests in Indian property website CommonfloorGoogle to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.  Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry. NEW DELHI Indian property search website Commonfloor.com has received funding from Google Capital, an equity fund backed by Google Inc, the online portal said in a statement on Thursday.Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.  NEW DELHI, Jan 8 Indian property search website Commonfloor.com has received funding from Google Capital, an equity fund backed by Google Inc, the online portal said in a statement on Thursday.Google Capital invests in Indian property website CommonfloorGoogle to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.  Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry. NEW DELHI Indian property search website Commonfloor.com has received funding from Google Capital, an equity fund backed by Google Inc, the online portal said in a statement on Thursday.Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.   
GOOG,Google Capital invests in Indian property website CommonfloorGoogle Capital invests in Indian property website CommonfloorGoogle to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.  Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry. NEW DELHI Indian property search website Commonfloor.com has received funding from Google Capital, an equity fund backed by Google Inc, the online portal said in a statement on Thursday.Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.   Google Capital invests in Indian property website CommonfloorGoogle to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.  Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry. NEW DELHI Indian property search website Commonfloor.com has received funding from Google Capital, an equity fund backed by Google Inc, the online portal said in a statement on Thursday.Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.  NEW DELHI, Jan 8 Indian property search website Commonfloor.com has received funding from Google Capital, an equity fund backed by Google Inc, the online portal said in a statement on Thursday.Google Capital invests in Indian property website CommonfloorGoogle to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.  Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry. NEW DELHI Indian property search website Commonfloor.com has received funding from Google Capital, an equity fund backed by Google Inc, the online portal said in a statement on Thursday.Google to start selling auto insurance in the U.S., analyst says SAN FRANCISCO, Jan 8 Google Inc may be moving into the U.S. auto insurance market with a shopping site for people to compare and buy policies, an analyst said on Thursday, as it continues to shift its attention to the automotive industry.   
APC,Thai PTT to conclude talks soon to buy 1.5 mln T of LNG a year from Anadarko's Mozambique plant RAYONG, Thailand, Jan 8 Thailand's PTT PCL  expects to conclude talks soon to buy 1.5 million tonnes of liquefied natural gas (LNG) a year from Anadarko Petroleum Corp's planned export plant in Mozambique, the Thai company's chief executive said on Thursday. 
ANTM,Anthem selects Gilead as primary supplier of hepatitis C drugs Jan 8 Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus. 
BAC,Bank of America shifts compliance team out of legal unit after OCC pressure -sourceBank of America shifts compliance team out of legal unit after OCC pressure -source ST. LOUIS Under pressure from its U.S. regulator, Bank of America has  shifted its compliance group from its legal department to its risk oversight group, a source familiar with the matter said.  Bank of America shifts compliance team out of legal unit after OCC pressure -source ST. LOUIS Under pressure from its U.S. regulator, Bank of America has  shifted its compliance group from its legal department to its risk oversight group, a source familiar with the matter said. ST. LOUIS, Jan 7 Under pressure from its U.S. regulator, Bank of America has  shifted its compliance group from its legal department to its risk oversight group, a source familiar with the matter said.Bank of America shifts compliance team out of legal unit after OCC pressure -source ST. LOUIS Under pressure from its U.S. regulator, Bank of America has  shifted its compliance group from its legal department to its risk oversight group, a source familiar with the matter said.  
BIIB,Biogen says mid-stage optic nerve treatment study succeedsUPDATE 2-Biogen experimental drug shows evidence of optic nerve repair Jan 8 An experimental drug from Biogen Idec Inc  showed evidence of biological repair of the optic nerve in a mid-stage study in patients with acute optic neuritis, an inflammation of the optic nerve that can lead to vision loss.  UPDATE 2-Biogen experimental drug shows evidence of optic nerve repair Jan 8 An experimental drug from Biogen Idec Inc  showed evidence of biological repair of the optic nerve in a mid-stage study in patients with acute optic neuritis, an inflammation of the optic nerve that can lead to vision loss. Jan 8 Biogen Idec Inc said on Thursday a mid-stage study of a new treatment for acute optic neuritis, an inflammation of the optic nerve that can lead to complete or partial loss of vision, showed evidence of biological repair of the visual system.UPDATE 2-Biogen experimental drug shows evidence of optic nerve repair Jan 8 An experimental drug from Biogen Idec Inc  showed evidence of biological repair of the optic nerve in a mid-stage study in patients with acute optic neuritis, an inflammation of the optic nerve that can lead to vision loss.  
CBS,Media embracing digital TV with strings attached NEW YORK/LAS VEGAS Jan 8 Media companies that are starting to allow their programs onto Internet-delivered TV and mobile devices are putting limits on digital rights as a safety hatch if problems arise with the new distribution systems, executives say. 
C,Morgan Stanley raises $1 billion for second credit fund NEW YORK, Jan 8 Morgan Stanley said it has raised about $1 billion for a new credit fund, the latest in a series of private equity-type vehicles it is raising despite a new regulation that limits the bank's own participation in such funds. 
STZ,Constellation Brands revenue rises on higher beer salesUPDATE 1-Constellation Brands raises profit forecast as beer sales rise Jan 8 Alcoholic beverage maker Constellation Brands Inc raised its full-year earnings forecast after reporting higher-than-expected quarterly sales and profit, helped by increased sales of its beer brands such as Corona and Modelo.  UPDATE 1-Constellation Brands raises profit forecast as beer sales rise Jan 8 Alcoholic beverage maker Constellation Brands Inc raised its full-year earnings forecast after reporting higher-than-expected quarterly sales and profit, helped by increased sales of its beer brands such as Corona and Modelo. Jan 8 Alcoholic beverage maker Constellation Brands Inc reported a 7 percent rise in quarterly revenue, helped by higher sales of its beer brands such as Corona and Modelo.UPDATE 1-Constellation Brands raises profit forecast as beer sales rise Jan 8 Alcoholic beverage maker Constellation Brands Inc raised its full-year earnings forecast after reporting higher-than-expected quarterly sales and profit, helped by increased sales of its beer brands such as Corona and Modelo.  
COST,RPT-BRIEF- Costco Wholesale reports December sales up 5 pctRPT-BRIEF- Costco Wholesale reports December sales up 5 pct Jan 8 Jan 8 Costco Wholesale Corp  :  * December sales rose 5 pct to $12.12 bln  * Dec comparable sales up 3%  * Dec comparable sales , excl fuel, up 8%  * December same-store sales view up 2.8 Pct, Incl Fuel -- Thomson Reuters Data   * Source text for Eikon   * Further company coverage  RPT-BRIEF- Costco Wholesale reports December sales up 5 pct Jan 8 Jan 8 Costco Wholesale Corp  :  * December sales rose 5 pct to $12.12 bln  * Dec comparable sales up 3%  * Dec comparable sales , excl fuel, up 8%  * December same-store sales view up 2.8 Pct, Incl Fuel -- Thomson Reuters Data   * Source text for Eikon   * Further company coverage Jan 8 Jan 8 Costco Wholesale Corp  :  * December sales rose 5 pct to $12.12 bln  * Dec comparable sales up 3%  * Dec comparable sales , excl fuel, up 8%  * December same-store sales view up 2.8 Pct, Incl Fuel -- Thomson Reuters Data   * Source text for Eikon   * Further company coverageRPT-BRIEF- Costco Wholesale reports December sales up 5 pct Jan 8 Jan 8 Costco Wholesale Corp  :  * December sales rose 5 pct to $12.12 bln  * Dec comparable sales up 3%  * Dec comparable sales , excl fuel, up 8%  * December same-store sales view up 2.8 Pct, Incl Fuel -- Thomson Reuters Data   * Source text for Eikon   * Further company coverage  
FB,Facebook buys video startup QuickFire Jan 8 Social network operator Facebook Inc  said it bought QuickFire Networks, a startup that helps view high-quality video with low bandwidth. 
F,Ford says 2014 China auto sales up 19 pct y/y SHANGHAI, Jan 8 Ford Motor Co and its Chinese joint ventures sold 1.11 million vehicles in China in 2014, up 19 percent from the previous year, the U.S. carmaker said on Thursday. 
GPS,UPDATE 2-Uniqlo owner suggests possible outlook hike after strong Q1 * Uniqlo Japan may need to raise prices again on weak yen   (Recasts, adds executive comments, details) 
GM,GM CEO sees U.S. auto market flattening out, but room for growthBRIEF-GM CEO Barra stands by target to return to profits in Europe in 2016 DETROIT, Jan 8 General Motors Co :  * CEO Mary Barra says core philosophy for company is to to build where the  BRIEF-GM CEO Barra stands by target to return to profits in Europe in 2016 DETROIT, Jan 8 General Motors Co :  * CEO Mary Barra says core philosophy for company is to to build where the DETROIT, Jan 8 General Motors Co Chief Executive Officer Mary Barra said she expected the U.S. auto market to flatten out this year, although growth is possible because of the strong economy and falling gasoline prices.BRIEF-GM CEO Barra stands by target to return to profits in Europe in 2016 DETROIT, Jan 8 General Motors Co :  * CEO Mary Barra says core philosophy for company is to to build where the  
GILD,Anthem selects Gilead as primary supplier of hepatitis C drugs Jan 8 Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus. 
GS,Exclusive: Ex-Goldman trader's fund up 51 percent playing energy's rise and fallGoldman led Canadian pack in value of M&A; deals in 2014Goldman led Canadian pack in value of M&A; deals in 2014 TORONTO Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold.  Goldman led Canadian pack in value of M&A; deals in 2014 TORONTO Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold. TORONTO, Jan 8 Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold.Goldman led Canadian pack in value of M&A; deals in 2014 TORONTO Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold.   Goldman led Canadian pack in value of M&A; deals in 2014Goldman led Canadian pack in value of M&A; deals in 2014 TORONTO Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold.  Goldman led Canadian pack in value of M&A; deals in 2014 TORONTO Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold. TORONTO, Jan 8 Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold.Goldman led Canadian pack in value of M&A; deals in 2014 TORONTO Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold.  A hedge fund run by former Goldman Sachs oil trader Jonathan Goldberg was among the biggest winners from violent energy market swings last year, piling on bullish bets during the fiercest winter in decades and then selling spot oil just before prices collapsed in the summer.Goldman led Canadian pack in value of M&A; deals in 2014Goldman led Canadian pack in value of M&A; deals in 2014 TORONTO Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold.  Goldman led Canadian pack in value of M&A; deals in 2014 TORONTO Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold. TORONTO, Jan 8 Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold.Goldman led Canadian pack in value of M&A; deals in 2014 TORONTO Goldman Sachs Group Inc  led investment banks advising on mergers and acquisitions in Canada in 2014, a year in which big international oil and gas deals were hot before oil prices turned cold.   
HOG,VCU 71, Davidson 65 (Updated: REMOVES extra line space before lede CORRECTS first-half rebounding, second sentence, fifth graph) 
M,Macy's to cut jobs, close 14 storesUPDATE 1-Macy's to cut jobs, close 14 stores Jan 8 Department store operator Macy's Inc  said it would close 14 stores in early spring 2015 and cut some jobs to focus on its popular services such as in-store pickups for online orders and "ship-from-store".  UPDATE 1-Macy's to cut jobs, close 14 stores Jan 8 Department store operator Macy's Inc  said it would close 14 stores in early spring 2015 and cut some jobs to focus on its popular services such as in-store pickups for online orders and "ship-from-store". Jan 8 Macy's Inc said it would close 14 stores in early spring 2015 and cut some jobs to boost its investment in technology and offset higher expense expected in healthcare and retirement plans.UPDATE 1-Macy's to cut jobs, close 14 stores Jan 8 Department store operator Macy's Inc  said it would close 14 stores in early spring 2015 and cut some jobs to focus on its popular services such as in-store pickups for online orders and "ship-from-store".  
MCD,McDonald's to cut 63 headquarters jobs in cost reduction Jan 8 McDonald's Corp will cut 63 jobs at its corporate headquarters as part of a plan to reduce costs by $100 million as it looks to increase sales and reverse traffic declines in its major markets. 
MSFT,UPDATE 2-Sony to delay sale of PlayStation 4 in China SHANGHAI, Jan 8 Sony Corp will delay sales of the PlayStation 4 gaming console in China, originally scheduled for Jan. 11, due to "various factors", the company said in a statement on Thursday. 
MS,SINGAPORE PRESS-Morgan Stanley fund mulls bulk sale of luxe units - Business TimesMorgan Stanley raises $1 billion for second credit fund NEW YORK, Jan 8 Morgan Stanley said it has raised about $1 billion for a new credit fund, the latest in a series of private equity-type vehicles it is raising despite a new regulation that limits the bank's own participation in such funds.  Morgan Stanley raises $1 billion for second credit fund NEW YORK, Jan 8 Morgan Stanley said it has raised about $1 billion for a new credit fund, the latest in a series of private equity-type vehicles it is raising despite a new regulation that limits the bank's own participation in such funds. A German core fund managed by Morgan Stanley is said to be exploring a bulk sale for its 23 units in the Draycott Eight condo, the Business Times reported. It has appointed two agents to help it find a buyer in a transaction which will be effected through the sale of shares in a company that owns the 22 four-bedders and a penthouse with a total strata area of 68,419 sq ft.Morgan Stanley raises $1 billion for second credit fund NEW YORK, Jan 8 Morgan Stanley said it has raised about $1 billion for a new credit fund, the latest in a series of private equity-type vehicles it is raising despite a new regulation that limits the bank's own participation in such funds.  
ORCL,Oracle's Kurian promoted to president, will lead software NEW YORK, Jan 8 Oracle Corp has promoted executive Thomas Kurian to the role of president, overseeing the tech company's software development, according to an internal memo seen by Reuters. 
PFE,Pfizer, FDA in talks on prescription details for key breast cancer drug Jan 8 Pfizer Inc said Thursday it has begun talks with the U.S. Food and Drug Administration to finalize the prescription label of its breast cancer drug palbociclib, in an indication the drug was likely closer to regulatory approval. 
SBUX,Starbucks says COO Alstead taking "extended unpaid leave"UPDATE 1-Starbucks COO Alstead taking 'extended unpaid leave' LOS ANGELES, Jan 8 Starbucks Corp on Thursday said Chief Operating Officer Troy Alstead, who as chief financial officer helped lead the coffee chain's massive and successful restructuring, is taking an extended unpaid leave from the coffee chain to spend more time with his family.  UPDATE 1-Starbucks COO Alstead taking 'extended unpaid leave' LOS ANGELES, Jan 8 Starbucks Corp on Thursday said Chief Operating Officer Troy Alstead, who as chief financial officer helped lead the coffee chain's massive and successful restructuring, is taking an extended unpaid leave from the coffee chain to spend more time with his family. LOS ANGELES, Jan 8 Starbucks Corp on Thursday said chief operating officer Troy Alstead, who also served for many years as the company's chief financial officer, is taking an extended unpaid leave from the coffee chain.UPDATE 1-Starbucks COO Alstead taking 'extended unpaid leave' LOS ANGELES, Jan 8 Starbucks Corp on Thursday said Chief Operating Officer Troy Alstead, who as chief financial officer helped lead the coffee chain's massive and successful restructuring, is taking an extended unpaid leave from the coffee chain to spend more time with his family.  
VZ,U.S. regulator wants faster speeds for Internet broadbandU.S. regulator wants faster speeds for Internet broadbandU.S. regulator wants faster speeds for Internet broadband WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.  U.S. regulator wants faster speeds for Internet broadband WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard. WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.U.S. regulator wants faster speeds for Internet broadband WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.   U.S. regulator wants faster speeds for Internet broadbandU.S. regulator wants faster speeds for Internet broadband WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.  U.S. regulator wants faster speeds for Internet broadband WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard. WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.U.S. regulator wants faster speeds for Internet broadband WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.  WASHINGTON, Jan 7 The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.U.S. regulator wants faster speeds for Internet broadbandU.S. regulator wants faster speeds for Internet broadband WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.  U.S. regulator wants faster speeds for Internet broadband WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard. WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.U.S. regulator wants faster speeds for Internet broadband WASHINGTON The head of the U.S. FCC on Wednesday proposed raising the definition of the high-speed Internet to downloads at 25 megabits per second (Mbps), a more than a six-fold increase from the current standard.   
YHOO,Starboard reiterates Yahoo should combine with AOLUPDATE 1-Starboard reiterates Yahoo should combine with AOLStarboard reiterates Yahoo should combine with AOL Activist-investor Starboard Value LP has reiterated that Yahoo Inc  should consider a merger with AOL Inc  and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions.  Starboard reiterates Yahoo should combine with AOL Activist-investor Starboard Value LP has reiterated that Yahoo Inc  should consider a merger with AOL Inc  and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions. Jan 8 Activist-investor Starboard Value LP has reiterated that Yahoo Inc should consider a merger with AOL Inc and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions.Starboard reiterates Yahoo should combine with AOL Activist-investor Starboard Value LP has reiterated that Yahoo Inc  should consider a merger with AOL Inc  and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions.   UPDATE 1-Starboard reiterates Yahoo should combine with AOLStarboard reiterates Yahoo should combine with AOL Activist-investor Starboard Value LP has reiterated that Yahoo Inc  should consider a merger with AOL Inc  and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions.  Starboard reiterates Yahoo should combine with AOL Activist-investor Starboard Value LP has reiterated that Yahoo Inc  should consider a merger with AOL Inc  and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions. Jan 8 Activist-investor Starboard Value LP has reiterated that Yahoo Inc should consider a merger with AOL Inc and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions.Starboard reiterates Yahoo should combine with AOL Activist-investor Starboard Value LP has reiterated that Yahoo Inc  should consider a merger with AOL Inc  and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions.  Jan 8 Yahoo Inc shareholder Starboard Value LP reiterated that the company should explore a combination with AOL Inc and cut costs to improve profits.UPDATE 1-Starboard reiterates Yahoo should combine with AOLStarboard reiterates Yahoo should combine with AOL Activist-investor Starboard Value LP has reiterated that Yahoo Inc  should consider a merger with AOL Inc  and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions.  Starboard reiterates Yahoo should combine with AOL Activist-investor Starboard Value LP has reiterated that Yahoo Inc  should consider a merger with AOL Inc  and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions. Jan 8 Activist-investor Starboard Value LP has reiterated that Yahoo Inc should consider a merger with AOL Inc and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions.Starboard reiterates Yahoo should combine with AOL Activist-investor Starboard Value LP has reiterated that Yahoo Inc  should consider a merger with AOL Inc  and cut costs to improve profits, spurred by media reports that Yahoo is exploring other large-scale acquisitions.   
